Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) FCF Margin (2016 - 2025)

Historic FCF Margin for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 400.48%.

  • Coherus Oncology's FCF Margin rose 6242400.0% to 400.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 139.88%, marking a year-over-year decrease of 106000.0%. This contributed to the annual value of 7.66% for FY2024, which is 604400.0% up from last year.
  • Per Coherus Oncology's latest filing, its FCF Margin stood at 400.48% for Q3 2025, which was up 6242400.0% from 4259.49% recorded in Q2 2025.
  • Coherus Oncology's 5-year FCF Margin high stood at 6111.66% for Q1 2024, and its period low was 1024.72% during Q3 2024.
  • Moreover, its 5-year median value for FCF Margin was 71.97% (2021), whereas its average is 453.93%.
  • In the last 5 years, Coherus Oncology's FCF Margin surged by 63240200bps in 2024 and then crashed by -65136200bps in 2025.
  • Over the past 5 years, Coherus Oncology's FCF Margin (Quarter) stood at 71.97% in 2021, then plummeted by -207bps to 220.59% in 2022, then surged by 94bps to 14.17% in 2023, then skyrocketed by 181bps to 11.52% in 2024, then tumbled by -3576bps to 400.48% in 2025.
  • Its FCF Margin was 400.48% in Q3 2025, compared to 4259.49% in Q2 2025 and 401.96% in Q1 2025.